Rheumatology

July 30, 2021

Take 5 minutes to catch up on Rheumatology Network's highlights from the week ending July 30, 2021.

July 29, 2021

“Our study confirms challenges in selecting an appropriate outcome in interventional studies targeting medication adherence and the ways in which the lack of guidance in this area hinders research and limits our ability to compare interventions and draw conclusions about their effectiveness,” stated investigators.

July 27, 2021

Roy Fleischmann, MD, discusses the recent Pfizer press release touching upon the safety of JAK inhibitors. He explains the recent scrutiny of JAKs, the concerns some rheumatologists have in regard to JAK inhibitors, and his personal opinions on prescribing JAK inhibiting drugs to his patients.

July 26, 2021

Patients with systemic lupus erythematosus presented more cardiovascular autonomic neuropathy, along with impaired health-related quality of life and parasympathetic function, when compared with a control cohort.

July 23, 2021

Take 5 minutes to catch up on Rheumatology Network's highlights from the week ending July 23, 2021.

July 15, 2021

In this observational cross-sectional study, investigators created a survey designed to understand the management and follow-up of patients during the COVID-19 pandemic in Latin American countries.

July 14, 2021

Research indicates that patients with autoimmune rheumatic diseases (AIRD) did not differ from the general population in terms of protective antibody responses against COVID-19.

July 13, 2021

On the latest episode of Overdrive, we sat down with Andrew L Concoff MD, FACR, CAQSM, to discuss value-based care, including the benefits, collaborate approach to working with payers, the revenue and cost savings, and how value-based care can support routine and consistent health visits.

July 08, 2021

Irene Kazmers, MD, discusses the heavy administrative burden placed on all practicing physicians in the last decade and why she chose to begin concierge, or membership medicine, a practice model that has "proven to be a tremendous fit for my career at this point in time and made it possible for me to continue as a practicing rheumatologist."

July 07, 2021

Patients with autoimmune inflammatory rheumatic diseases had an increased risk of testing positive for SARS-CoV-2 and worse clinical outcomes of COVID-19, including death, although disease-modifying antirheumatic drugs (DMARDs) did not increase the risk of these outcomes.